Market Trends of Conjunctivitis Treatment Industry
This section covers the major market trends shaping the Conjunctivitis Treatment Market according to our research experts:
Allergic Conjunctivitis is Expected to Witness a Steady Growth in the Conjunctivitis Treatment Over the Forecast Period
Allergic conjunctivitis is expected to hold a significant market share over the forecast period. Allergic conjunctivitis is common and causes sudden swelling in the eyelids and ocular itching. People having allergies are more likely to develop allergic conjunctivitis.
As per the Nature article published in April 2022, approximately 10% of the sample population had allergic conjunctivitis. In India, the prevalence of allergic conjunctivitis was 12.22% among those aged between five and 15 years. Also, the NCBI article published in January 2021 mentioned that more than half of the patients report daily symptoms as seasonal or perennial and around 75% consider their symptoms to be severe. The same source also mentioned that there were between 1.2 and 10.6 cases of vernal keratoconjunctivitis per 10,000 individuals in Europe. Such incidence of allergic conjunctivitis is expected to drive the demand for effective treatment, contributing to the growth of the studied segment.
Treatment for acute conjunctivitis includes oral or over-the-counter (OTC) drugs that reduce the release of histamine. Also, anti-inflammatory or anti-inflammation eye drops are available quickly and are found to relieve acute conjunctivitis. Hence, this segment is expected to witness steady growth during the forecast period.
North America is Expected to Dominate the Conjunctivitis Treatment Market Over the Forecast Period
North America is expected to dominate the market, owing to factors such as the easy availability of effective treatment products and high awareness among consumers regarding conjunctivitis in the region. As per the National Library Medicine article published in February 2020, conjunctivitis affects more than 6 million people across the United States every year. The estimated cost for the disease is around USD 377 million to USD 857 million per year. Conjunctivitis is found to be the most frequent disease in the country and affects 15% to 40% of the population, and is seen frequently in spring and summer.
Also, the NCBI article published in January 2021 mentioned that seasonal or perennial allergic conjunctivitis is the most prevalent form of allergic conjunctivitis, with more than 95% of ocular allergy cases in the United States. It is observed in both sexes and affects between 15% and 40% of the population. Such prevalence of conjunctivitis in the United States is expected to drive the demand for effective treatment, thereby contributing to the market's growth during the forecast period.
Due to better healthcare services and the high number of people suffering from conjunctivitis in the United States, the market is expected to hold the largest share shortly.
Also, the high prevalence of conjunctivitis in Canada is expected to contribute to the market's growth over the forecast period. As per the BMC article published in October 2022, it is estimated that 21% of Canadians have dry eyes. Such prevalence of conjunctivitis is expected to contribute to market growth in Canada.
Similarly, the high prevalence of conjunctivitis is expected to contribute to the driving demand for conjunctivitis treatment. As per the World Allergy Organization Journal published in December 2020, 10 medical centers reported a prevalence of allergic rhinoconjunctivitis in children of 11.6%, while adolescents reported 15.4%. Such prevalence of conjunctivitis in Mexico is expected to contribute to the market's growth.
Thus, the factors mentioned above are expected to drive the market's growth during this region's forecast period.
